August 2010 in “The Journal of urology/The journal of urology” Male pattern baldness may be linked to prostate cancer risk.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
February 2007 in “Lancet Oncology” Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.
October 2006 in “Clinical Cancer Research” Antioxidants can block the cancer-fighting effects of doxorubicin.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
December 2004 in “SUNScholar (Stellenbosch University)” Certain genetic markers can indicate a person's risk of developing prostate cancer.
January 2019 in “Central European Journal of Urology”
237 citations
,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
116 citations
,
May 1992 in “The American Journal of Medicine” Flutamide rarely causes liver toxicity in prostate cancer patients.
108 citations
,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
65 citations
,
September 2017 in “British Journal of Cancer” Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.
57 citations
,
November 2006 in “International Journal of Cancer” A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
34 citations
,
February 2013 in “Journal of The American Academy of Dermatology” Vertex pattern hair loss linked to higher prostate cancer risk.
29 citations
,
February 2016 in “Scandinavian journal of urology” Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.
29 citations
,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
12 citations
,
October 2018 in “Aging male/The aging male” Higher BMI and lower testosterone are linked to more aggressive prostate cancer.
6 citations
,
June 2016 in “Journal of receptor and signal transduction research” Minoxidil increases calcium levels and kills prostate cancer cells independently of calcium.
3 citations
,
January 2017 in “Revista chilena de nutrición” Certain natural compounds called terpenes may help prevent prostate cancer.
2 citations
,
August 2025 in “Cureus” Taking finasteride before surgery reduces blood loss in prostate procedures.
2 citations
,
January 2023 in “PubMed” Targeting FGF5 could help treat prostate cancer.
1 citations
,
July 2024 in “The International Journal of Medical Science and Health Research” 5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
No link was found between hair patterns and prostate cancer risk in South Indian men.
December 2024 in “Journal of Cancer Therapy and Research” Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.
Certain plasma proteins are linked to prostate cancer risk and could help in early detection and treatment.
October 2017 in “The Journal of Urology” Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
April 2016 in “Journal of Urology and Nephrology Open Access” Thermobalancing Therapy can treat enlarged prostate and improve men's quality of life.
March 2016 in “National Repository of Dissertations in Serbia” Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
August 2015 in “International Journal of Genetics and Molecular Biology” Certain genetic markers may increase or decrease prostate cancer risk.
Adherence to finasteride treatment for prostate issues is generally low.